Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | SCLC | Case Report

Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review

Authors: Zhe Cai, Linwei Zuo, Fangfang Hu, Huiyan You, Xiangtong Lu, Shousheng Liao, Fanrong Liu, Lixiang Li, Wenyong Huang

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

To present an unusual case of abnormal LCA expression and CD43 in SCLC and to review the reported literature to avoid potential diagnostic pitfalls.

Case presentation

A 73-year-old male patient suffered from persistent back pain for more than one month. MRI revealed a compression fracture of the L1-L5 vertebra. A CT scan revealed multiple nodules and masses at the left root of the neck, lung hilum and mediastinum, and multiple areas of bony destruction of the ribs. Histology of the tumor revealed that small and round cells were arranged in nests with areas of necrosis. The tumor cells were round to ovoid with scant cytoplasm and indistinct cell borders. The nuclear chromatin was finely granular, and the nucleoli were absent or inconspicuous. Immunohistochemically, the tumor cells were positive for cytokeratin, TTF-1, POU2F3, LCA, and CD43.

Conclusion

This report highlights a potential diagnostic pitfall in the diagnosis of SCLC, urges pathologists to exercise caution in cases of LCA and CD43 positivity and illustrates the need for further immunohistochemical studies to avoid misdiagnosis.
Literature
1.
go back to reference Rheinländer A, Schraven B. U Bommhardt CD45 in human physiology and clinical medicine. Immunol Lett. 2018;196:22–32.CrossRefPubMed Rheinländer A, Schraven B. U Bommhardt CD45 in human physiology and clinical medicine. Immunol Lett. 2018;196:22–32.CrossRefPubMed
2.
go back to reference Houreih MA, Eyden BP, Reeve N, et al. Aberrant leukocyte common antigen expression in metastatic small cell lung carcinoma: a rare finding and a potential diagnostic pitfall. Appl Immunohistochem Mol Morphol. 2007;15:236–38.CrossRefPubMed Houreih MA, Eyden BP, Reeve N, et al. Aberrant leukocyte common antigen expression in metastatic small cell lung carcinoma: a rare finding and a potential diagnostic pitfall. Appl Immunohistochem Mol Morphol. 2007;15:236–38.CrossRefPubMed
3.
go back to reference McDonnell JM, Beschorner WE, Kuhajda FP, et al. Common leukocyte antigen staining of a primitive sarcoma. Cancer. 1987;59:1438–41.CrossRefPubMed McDonnell JM, Beschorner WE, Kuhajda FP, et al. Common leukocyte antigen staining of a primitive sarcoma. Cancer. 1987;59:1438–41.CrossRefPubMed
4.
go back to reference Nandedkar MA, Palazzo J, Abbondanzo SL, et al. CD45 (leukocyte common antigen) immunoreactivity in metastatic undifferentiated and neuroendocrine carcinoma: a potential diagnostic pitfall. Mod Pathol. 1998;11(12):1204–10.PubMed Nandedkar MA, Palazzo J, Abbondanzo SL, et al. CD45 (leukocyte common antigen) immunoreactivity in metastatic undifferentiated and neuroendocrine carcinoma: a potential diagnostic pitfall. Mod Pathol. 1998;11(12):1204–10.PubMed
5.
go back to reference Seethala RR, Pasha TL, Raghunath PN, et al. The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol. 2008;16(2):165–72.CrossRefPubMed Seethala RR, Pasha TL, Raghunath PN, et al. The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol. 2008;16(2):165–72.CrossRefPubMed
6.
go back to reference Judkins AR, Montone KT, LiVolsi VA, et al. Sensitivity and specificity of antibodies on necrotic tumor tissue. Am J Clin Pathol. 1998;110:641–6.CrossRefPubMed Judkins AR, Montone KT, LiVolsi VA, et al. Sensitivity and specificity of antibodies on necrotic tumor tissue. Am J Clin Pathol. 1998;110:641–6.CrossRefPubMed
7.
go back to reference Cartagena N Jr, Suster S, Cabello-Inchausti B. Artifactual distortion of cells simulating metastatic small cell carcinoma in the bone marrow. Ann Clin Lab Sci. 1993;23:130–6.PubMed Cartagena N Jr, Suster S, Cabello-Inchausti B. Artifactual distortion of cells simulating metastatic small cell carcinoma in the bone marrow. Ann Clin Lab Sci. 1993;23:130–6.PubMed
8.
go back to reference Fu Q, Cash SE, Andersen JJ, et al. CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target. Int J Cancer. 2013;132(8):1761–70.CrossRefPubMed Fu Q, Cash SE, Andersen JJ, et al. CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target. Int J Cancer. 2013;132(8):1761–70.CrossRefPubMed
9.
go back to reference Gustmann C, Altmannsberger M, Osborn M, et al. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-hodgkin’s lymphomas. Am J Pathol. 1991;138:1413–22.PubMedPubMedCentral Gustmann C, Altmannsberger M, Osborn M, et al. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-hodgkin’s lymphomas. Am J Pathol. 1991;138:1413–22.PubMedPubMedCentral
10.
go back to reference Lasota J, Hyjek E, Koo CH, et al. Cytokeratin-positive large-cell lymphomas of B-cell lineage. A study of five phenotypically unusual cases verified by polymerase chain reaction. Am J Surg Pathol. 1996;20:346–54.CrossRefPubMed Lasota J, Hyjek E, Koo CH, et al. Cytokeratin-positive large-cell lymphomas of B-cell lineage. A study of five phenotypically unusual cases verified by polymerase chain reaction. Am J Surg Pathol. 1996;20:346–54.CrossRefPubMed
11.
go back to reference Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15(12):1823–35.CrossRefPubMedPubMedCentral Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15(12):1823–35.CrossRefPubMedPubMedCentral
12.
go back to reference Brady NJ, Bagadion AM, Singh R, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.CrossRefPubMedPubMedCentral Brady NJ, Bagadion AM, Singh R, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.CrossRefPubMedPubMedCentral
13.
go back to reference Baine MK, Febres-Aldana CA, Chang JC, et al. POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in Neuroendocrine-Low SCLC. J Thorac Oncol. 2022;17(9):1109–21.CrossRefPubMedPubMedCentral Baine MK, Febres-Aldana CA, Chang JC, et al. POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in Neuroendocrine-Low SCLC. J Thorac Oncol. 2022;17(9):1109–21.CrossRefPubMedPubMedCentral
14.
go back to reference Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32(13–14):915–28.CrossRefPubMedPubMedCentral Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32(13–14):915–28.CrossRefPubMedPubMedCentral
15.
go back to reference Dmitriy Sonkin A, Thomas. Beverly A Teicher.Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?Lung. Cancer Manag. 2019;8(2):LMT13. Dmitriy Sonkin A, Thomas. Beverly A Teicher.Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?Lung. Cancer Manag. 2019;8(2):LMT13.
16.
go back to reference Ryota Matsuoka H, Kawai T, Ito D, Matsubara. Determining whether YAP1 and POU2F3 are antineuroendocrine factors. J Thorac Oncol. 2022;17:1070–3.CrossRefPubMed Ryota Matsuoka H, Kawai T, Ito D, Matsubara. Determining whether YAP1 and POU2F3 are antineuroendocrine factors. J Thorac Oncol. 2022;17:1070–3.CrossRefPubMed
17.
go back to reference Marina K, Baine M-S, Hsieh W, Victoria Lai JV, Egger AA, Jungbluth Y, Daneshbod A, Beras R, Spencer J, Lopardo F, Bodd J, Montecalvo JL, Sauter, Jason C, Chang, Darren J, Buonocore, William D, Travis T, Sen JT, Poirier CM, Rudin. Natasha Rekhtman. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823–35.CrossRef Marina K, Baine M-S, Hsieh W, Victoria Lai JV, Egger AA, Jungbluth Y, Daneshbod A, Beras R, Spencer J, Lopardo F, Bodd J, Montecalvo JL, Sauter, Jason C, Chang, Darren J, Buonocore, William D, Travis T, Sen JT, Poirier CM, Rudin. Natasha Rekhtman. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823–35.CrossRef
18.
go back to reference Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35:36–50.CrossRefPubMed Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35:36–50.CrossRefPubMed
19.
go back to reference Matsui S, Haruki T, Oshima Y, et al. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Thorac Cancer. 2022;13(8):1184–92.CrossRefPubMedPubMedCentral Matsui S, Haruki T, Oshima Y, et al. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Thorac Cancer. 2022;13(8):1184–92.CrossRefPubMedPubMedCentral
Metadata
Title
Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review
Authors
Zhe Cai
Linwei Zuo
Fangfang Hu
Huiyan You
Xiangtong Lu
Shousheng Liao
Fanrong Liu
Lixiang Li
Wenyong Huang
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
SCLC
SCLC
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-03005-w

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine